Abstract
Trilaciclib, an intravenous (IV) kinase inhibitor that protects hematopoeitic stem and progenitor cells during chemotherapy exposure, is FDA approved to decrease the incidence of chemotherapy-induced myelosuppression in patients (pts) with extensive-stage small cell lung cancer based on data from three randomized, placebo-controlled phase II trials. In another randomized phase II trial in pts with triple-negative breast cancer, administering trilaciclib prior to chemotherapy had limited myeloprotective effects, but improved overall survival (OS).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
